FindTrial
Sign In

CM512

BIOLOGICAL7 trials

Sponsors

Keymed Biosciences Co.Ltd, Beijing Keymed Biosciences Co., Ltd.

Conditions

Atopic DermatitisAtopic Dermatitis (AD)Chronic Obstructive Pulmonary DiseaseChronic Rhinosinusitis With Nasal PolyposisChronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Phase 1

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
CompletedNCT06553209
Keymed Biosciences Co.LtdAtopic Dermatitis
Start: 2024-09-02End: 2025-09-12Updated: 2025-09-22

Phase 2

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）
CompletedNCT06930612
Beijing Keymed Biosciences Co., Ltd.Chronic Rhinosinusitis With Nasal Polyposis
Start: 2025-05-16End: 2026-07-10Updated: 2026-08-18
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
RecruitingNCT06947980
Keymed Biosciences Co.LtdAtopic Dermatitis
Start: 2025-06-19End: 2026-11-07Target: 200Updated: 2025-08-17
A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Not yet recruitingNCT06980142
Keymed Biosciences Co.LtdChronic Obstructive Pulmonary Disease
Start: 2025-06-20End: 2028-03-17Target: 204Updated: 2025-05-20
A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
RecruitingNCT07230483
Keymed Biosciences Co.LtdAtopic Dermatitis (AD)
Start: 2025-12-31End: 2027-12-31Target: 246Updated: 2025-11-17
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
Not yet recruitingNCT07519577
Keymed Biosciences Co.LtdChronic Rhinosinusitis With Nasal Polyposis
Start: 2026-05-31End: 2028-05-31Target: 120Updated: 2026-06-30

Phase 3

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)
Not yet recruitingNCT07807826
Beijing Keymed Biosciences Co., Ltd.Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Start: 2026-10-01End: 2028-07-01Target: 240Updated: 2026-09-08

Related Papers

First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity
Frontiers in Immunology2026-05-28